US OptionsDetailed Quotes
SVRA241220P1000
- 0.00
- 0.000.00%
15min DelayClose Nov 29 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest1.00Strike Price0.00Turnover0.00%IV70.24%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier20DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma33.60Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Savara Stock Discussion
Sign in to post a comment
$Savara (SVRA.US)$ Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024
2 MINUTES AGO, 8:05 AM EST
VIA BUSINESSWIRE
Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that an encore presentation of results from...
2 MINUTES AGO, 8:05 AM EST
VIA BUSINESSWIRE
Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that an encore presentation of results from...
2
5
$Savara (SVRA.US)$
Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024
Savara announced an encore presentation of Phase 3 IMPALA-2 trialresults for Molgramostim inhalation solution in patients with autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the upcoming British Thoracic Society Winter Meet...
Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024
Savara announced an encore presentation of Phase 3 IMPALA-2 trialresults for Molgramostim inhalation solution in patients with autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the upcoming British Thoracic Society Winter Meet...
$Savara (SVRA.US)$
After a productive pre-BLA meeting with the FDA, we are working diligently to initiate a rolling submission for MOLBREEVI by the end of this year, with plans to complete the BLA submission by the end of 1Q 2025—thus enabling a potential approval in the U.S. by the end of 2025, if priority review is granted,” said Matt Pauls, Chair and CEO, Savara. “BLA submission, coupled with the submission of the MAA to the EMA by the end of 2025, are major regulatory mileston...
After a productive pre-BLA meeting with the FDA, we are working diligently to initiate a rolling submission for MOLBREEVI by the end of this year, with plans to complete the BLA submission by the end of 1Q 2025—thus enabling a potential approval in the U.S. by the end of 2025, if priority review is granted,” said Matt Pauls, Chair and CEO, Savara. “BLA submission, coupled with the submission of the MAA to the EMA by the end of 2025, are major regulatory mileston...
1
$Savara (SVRA.US)$
Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of “The Balancing Act®” Airing on Lifetime® TV
Savara Inc. (Nasdaq: SVRA) announced that a new episode of The Balancing Act® on Lifetime TV's Behind the Mystery™ series is featuring autoimmune Pulmonary Alveolar Proteinosis (aPAP). The episode, sponsored by Savara, focuses on an aPAP patient's diagnostic journey and includes insights from Dr. Bruce Trapn...
Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of “The Balancing Act®” Airing on Lifetime® TV
Savara Inc. (Nasdaq: SVRA) announced that a new episode of The Balancing Act® on Lifetime TV's Behind the Mystery™ series is featuring autoimmune Pulmonary Alveolar Proteinosis (aPAP). The episode, sponsored by Savara, focuses on an aPAP patient's diagnostic journey and includes insights from Dr. Bruce Trapn...
$Savara (SVRA.US)$ Phase 3 update will be presented Monday.. keep watch
$Savara (SVRA.US)$ Reuters· just
Savara Announces Expanded Access Program (Eap) for Molgramostim Inhalation Solution (Molgramostim) for Patients With Autoimmune Pulmonary Alveolar Proteinosis (Apap)
Savara Announces Expanded Access Program (Eap) for Molgramostim Inhalation Solution (Molgramostim) for Patients With Autoimmune Pulmonary Alveolar Proteinosis (Apap)
$Savara (SVRA.US)$
Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Savara Inc. (Nasdaq: SVRA) has announced the Savara Early Access Program, an Expanded Access Program (EAP) for molgramostim inhalation solution to treat patients with autoimmune pulmonary alveolar proteinosis (aPAP). This program allows physicians to request molgramostim for eligible aPAP patients in select re...
Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Savara Inc. (Nasdaq: SVRA) has announced the Savara Early Access Program, an Expanded Access Program (EAP) for molgramostim inhalation solution to treat patients with autoimmune pulmonary alveolar proteinosis (aPAP). This program allows physicians to request molgramostim for eligible aPAP patients in select re...
Morning Movers
Gapping up
$Boeing (BA.US)$ shares rose by 4.1% in premarket US trading on Monday after the company tentatively agreed to a 25% pay increase for its biggest union, possibly averting a damaging strike.
Crypto-related stocks such as digital coin exchange $Coinbase (COIN.US)$ and crypto miners $CleanSpark (CLSK.US)$ and $MARA Holdings (MARA.US)$ advanced prior to the opening bell, buoyed by Bitcoin's gain, which ex...
Gapping up
$Boeing (BA.US)$ shares rose by 4.1% in premarket US trading on Monday after the company tentatively agreed to a 25% pay increase for its biggest union, possibly averting a damaging strike.
Crypto-related stocks such as digital coin exchange $Coinbase (COIN.US)$ and crypto miners $CleanSpark (CLSK.US)$ and $MARA Holdings (MARA.US)$ advanced prior to the opening bell, buoyed by Bitcoin's gain, which ex...
31
5
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
No comment yet
zezzzo : When
Trytosaveabit OP zezzzo : Meeting November 27/29
Trytosaveabit OP zezzzo : If you click the chat post! It will expand the whole post if it’s to long to fit in chat! Just saying incase you didn’t know? GL
zezzzo : According to your experience, do you expect this stock to rise or fall?
Trytosaveabit OP zezzzo : So it’s been on a decent daily uptrend for over a week! The doji on the daily tells me right now that the momentum could be slowing down? So right now it can go either way. But if some good news comes? I look for it to continue up! If Friday it can continue up and close above VWAP and cross above the 20MA? I would take that as bullish momentum continuing! So to me it says if I want to enter? Drop to the 3 minute chart to look for a in but set a SL! NFA just what I’m seeing! Happy thanksgiving!